FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567696265> ?p ?o ?g. }

• W1567696265 endingPage "4102" @default.
• W1567696265 startingPage "4102" @default.
• W1567696265 abstract "We appreciate the comments of Dr. Marucci regarding our paper entitled, “Treatment of Pituitary Neoplasms With Temozolomide: A Review”.1 The 6 patients with carcinomas who responded to treatment were the reported patients in the literature. MGMT immunoexpression was only available in 3 of them, and it was negative.1 The 57% of carcinomas that demonstrated low MGMT immunoexpression were from a retrospective study of paraffin-embedded tissues.2 Dr. Marucci raises an important question, can MGMT immunostaining predict response to temozolomide therapy? At present, this is controversial. Several, but not all, publications conclude that MGMT immunoreactivity is a reliable indicator of therapeutic response to temozolomide in patients with pituitary adenomas. With respect to the use of immunohistochemistry, 2 important problems must be addressed, the method and its interpretation. If tissue fixation, processing, and immunostaining are properly performed, then the immunohistochemical findings are reliable. This has been proven by several authors. Obviously, when methods are suboptimally applied, the results are not acceptable. The dispute is not with the method but with its interpretation. In some tumors, every neoplastic cell is MGMT- immunonegative, whereas in others every cell is immunopositive. The former tumors appear to respond to temozolomide, whereas the latter tumors do not. The challenge is that many pituitary tumors consist of a mixture of MGMT-immunonegative and -immunopositive cells. How should such results be interpreted? Maybe the MGMT-immunonegative cell would respond, whereas the immunopositive cells would be resistant? Can immunonegative cells transform to immunopositive cells or vice versa? Is it possible that temozolomide administration depletes MGMT causing transformation of immunopositive cells to immunonegative cells resulting in a beneficial response to temozolomide? Other genetic and/or epigenetic factors may also exist that could affect temozolomide responsiveness. Lastly, Dr. Marucci alludes to the demonstration of promoter methylation and its greater accuracy in predicting a therapeutic response. In published studies and in our experience, perfect correlation between MGMT staining and methylation status has not been achieved. Clearly, all available methods of assessing likelihood of temozolomide response should be used. We feel strongly that MGMT immunoreactivity is valuable and should be pursued. Obviously, more work is needed to address these issues." @default.
• W1567696265 created "2016-06-24" @default.
• W1567696265 creator A5002541996 @default.
• W1567696265 creator A5012446895 @default.
• W1567696265 creator A5049749614 @default.
• W1567696265 date "2011-03-08" @default.
• W1567696265 modified "2023-09-25" @default.
• W1567696265 title "Reply to treatment of pituitary neoplasms with temozolomide" @default.
• W1567696265 cites W2006179410 @default.
• W1567696265 cites W2063520958 @default.
• W1567696265 doi "https://doi.org/10.1002/cncr.25998" @default.
• W1567696265 hasPublicationYear "2011" @default.
• W1567696265 type Work @default.
• W1567696265 sameAs 1567696265 @default.
• W1567696265 citedByCount "1" @default.
• W1567696265 countsByYear W15676962652012 @default.
• W1567696265 crossrefType "journal-article" @default.
• W1567696265 hasAuthorship W1567696265A5002541996 @default.
• W1567696265 hasAuthorship W1567696265A5012446895 @default.
• W1567696265 hasAuthorship W1567696265A5049749614 @default.
• W1567696265 hasBestOaLocation W15676962651 @default.
• W1567696265 hasConcept C104317684 @default.
• W1567696265 hasConcept C126322002 @default.
• W1567696265 hasConcept C142724271 @default.
• W1567696265 hasConcept C143998085 @default.
• W1567696265 hasConcept C204232928 @default.
• W1567696265 hasConcept C2776194525 @default.
• W1567696265 hasConcept C2777389519 @default.
• W1567696265 hasConcept C2781449511 @default.
• W1567696265 hasConcept C33288867 @default.
• W1567696265 hasConcept C4224716 @default.
• W1567696265 hasConcept C502942594 @default.
• W1567696265 hasConcept C55493867 @default.
• W1567696265 hasConcept C71924100 @default.
• W1567696265 hasConcept C86803240 @default.
• W1567696265 hasConcept C91965660 @default.
• W1567696265 hasConceptScore W1567696265C104317684 @default.
• W1567696265 hasConceptScore W1567696265C126322002 @default.
• W1567696265 hasConceptScore W1567696265C142724271 @default.
• W1567696265 hasConceptScore W1567696265C143998085 @default.
• W1567696265 hasConceptScore W1567696265C204232928 @default.
• W1567696265 hasConceptScore W1567696265C2776194525 @default.
• W1567696265 hasConceptScore W1567696265C2777389519 @default.
• W1567696265 hasConceptScore W1567696265C2781449511 @default.
• W1567696265 hasConceptScore W1567696265C33288867 @default.
• W1567696265 hasConceptScore W1567696265C4224716 @default.
• W1567696265 hasConceptScore W1567696265C502942594 @default.
• W1567696265 hasConceptScore W1567696265C55493867 @default.
• W1567696265 hasConceptScore W1567696265C71924100 @default.
• W1567696265 hasConceptScore W1567696265C86803240 @default.
• W1567696265 hasConceptScore W1567696265C91965660 @default.
• W1567696265 hasIssue "17" @default.
• W1567696265 hasLocation W15676962651 @default.
• W1567696265 hasOpenAccess W1567696265 @default.
• W1567696265 hasPrimaryLocation W15676962651 @default.
• W1567696265 hasRelatedWork W1482952281 @default.
• W1567696265 hasRelatedWork W1972627320 @default.
• W1567696265 hasRelatedWork W2019660019 @default.
• W1567696265 hasRelatedWork W2080615689 @default.
• W1567696265 hasRelatedWork W2242689536 @default.
• W1567696265 hasRelatedWork W2413359840 @default.
• W1567696265 hasRelatedWork W2567075592 @default.
• W1567696265 hasRelatedWork W2765717542 @default.
• W1567696265 hasRelatedWork W3026256006 @default.
• W1567696265 hasRelatedWork W3187205508 @default.
• W1567696265 hasVolume "117" @default.
• W1567696265 isParatext "false" @default.
• W1567696265 isRetracted "false" @default.
• W1567696265 magId "1567696265" @default.
• W1567696265 workType "article" @default.